Phathom Pharmaceuticals (PHAT) Total Non-Current Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Total Non-Current Liabilities for 9 consecutive years, with $667.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 3.61% year-over-year to $667.8 million; the TTM figure through Jun 2026 stood at $667.8 million (up 3.61% YoY), while the FY2025 annual figure was $693.3 million, up 11.75% from the prior year.
• Total Non-Current Liabilities advanced to $667.8 million in Q2 2026 per PHAT's latest filing, from $638.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $693.3 million in Q4 2025 and bottomed at $103.5 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $449.9 million across 5 years, with a median of $519.0 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 171.94% — and 2026, when it increased 2.82%.
• Phathom Pharmaceuticals' Total Non-Current Liabilities stood at $232.1 million in 2022, then soared by 105.45% to $476.9 million in 2023, then jumped by 30.09% to $620.4 million in 2024, then increased by 11.75% to $693.3 million in 2025, then slipped by 3.67% to $667.8 million in 2026.
• Business Quant data shows PHAT's Total Non-Current Liabilities at $667.8 million in Q2 2026, $638.6 million in Q1 2026, and $693.3 million in Q4 2025.